Bringing the fundamentals into focus…
Back to Nuvectis Pharma, Inc.
How Nuvectis Pharma, Inc. stacks up
NVCT · against 487 other Healthcare companies of similar size
Valuation
33/ 100
Below the middle of the pack.
Ranked #294 of 488 · scores higher than 39% of peers
Bars: peers in each 10-point band of the valuation score35 peers with a valuation score of 30–39, including NVCT · Click a bar to see the companies
Why valuation scores 33?
Weighted metrics compared with all Healthcare companies.Mainly because of its earnings yield, which is weaker than most Healthcare peers.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -4.4% vs peer median 1.5%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Free cash flow yield: -3.1% vs peer median 0.0%
- EBITDA yield is not reported, so it is left out of the score.
Metric by metric
Position: dot = NVCT, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | NVCT | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 474 reported | -6.8% | 0.8% | 26% | 30% | |
| EBITDA yieldHigher is better · 491 reported | Not reported | 3.8% | — | — | 50% |
| Free cash flow yieldHigher is better · 205 reported | -3.1% | -3.9% | 52% | 20% | |
| Book yieldHigher is better · 485 reported | 1.8% | 45.6% | 6% | Context only |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by valuation score
Top 5 and the companies ranked around NVCT| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 1 | 2.9B HKD (≈$365M) | 99 | 84 | |
| 1 | 89.9B JPY (≈$611M) | 99 | 68 | |
| 1 | 3.1B HKD (≈$396M) | 99 | 61 | |
| 1 | 6.50T IDR (≈$403M) | 99 | 69 | |
| 294 | 1.2B USD | 33 | ||
| 294 | 389M USD | 33 | 33 | |
| 294 | 338M USD | 33 | ||
| 294 | 469M USD | 33 | 50 | |
| 294 | 631M USD | 33 | ||
| 294 | 455M USD | 33 | 53 | |
| 301 | 6.2B CNY (≈$861M) | 32 | 35 | |
| 301 | 2.8B CNY (≈$392M) | 32 | 42 | |
| 301 | 6.0B CNY (≈$840M) | 32 | 35 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score